Beilschmiedia species: from chemistry to pharmacological values.

Authors

Pham Thi Bich Dao, Nguyen Ngoc Linh, Huynh Thi Ngoc Ni, Nguyen Thi Hanh, Chu Anh Van, Ninh The Son

Published in

Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents. Volume 35. Issue 3. Pages 439-471. Epub Jan 19, 2026.

Abstract

Beilschmiedia (the family Lauraceae) is a large tropical genus containing species traditionally used to treat rheumatism, tumors, malaria, infections, and others. Despite extensive ethnomedicinal applications, a comprehensive evaluation of its phytochemistry and pharmacology remains limited. This review aims to consolidate current knowledge on the phytochemical diversity, biosynthetic and synthetic pathways, pharmacological potential, and chemical modifications of Beilschmiedia species. Relevant studies were retrieved from PubMed, Scopus, Web of Science, and Google Scholar up to September 2025 using "Beilschmiedia" as the main keyword. Eligible publications included original reports on phytochemical isolation, structure elucidation, biosynthetic studies, synthetic modification, and pharmacological evaluation, whereas botanical identifications were excluded. Over 240 compounds were characterized from 30 Beilschmiedia species, encompassing tetracyclic polyketides, alkaloids, terpenoids, phytosterols, lignans, neolignans, flavonoids, alkamides, and others. Endiandric acids and cyclobutane/oxetane-type neolignans, possessing unique skeletons, could be chemotaxonomic significance. Pharmacological studies have revealed diverse activities, such as cytotoxic, antimicrobial, antimalarial, antioxidant, anti-inflammatory, antidiabetic, and cholinesterase-inhibitory activities. Advances in biosynthesis, total synthesis, and semi-synthetic modification have facilitated the exploration of structure-activity relationships. Beilschmiedia represents a valuable reservoir of chemically novel and biologically active compounds. Future research should expand phytochemical surveys to underexplored species, integrate metabolomic and genomic approaches, and conduct advanced pharmacological studies, including in vivo validation and formulation development.

PMID:
42446653
Bibliographic data and abstract were imported from PubMed on 14 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.